 TEL AVIV, Israel and RALEIGH, NC, June 7, 2021 PRNewswire -- RedHill Biopharma Ltd. Nasdaq: RDHL RedHill or the Company, a specialty biopharmaceutical company, today announced that it has completed enrollment and randomized the last patient in the global Phase 23 study with opaganib Yeliva, ABC2946401 in patients hospitalized with severe COVID-19 pneumonia NCT04467840. 